BioNTech SE (BNTX)
| Market Cap | 23.30B +2.3% |
| Revenue (ttm) | 3.23B +2.1% |
| Net Income | -1.44B |
| EPS | -5.89 |
| Shares Out | 252.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 668,712 |
| Open | 92.54 |
| Previous Close | 90.93 |
| Day's Range | 91.67 - 93.48 |
| 52-Week Range | 79.52 - 124.00 |
| Beta | 1.37 |
| Analysts | Buy |
| Price Target | 122.60 (+33.06%) |
| Earnings Date | May 5, 2026 |
About BNTX
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli... [Read more]
Financial Performance
In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price target is $122.6, which is an increase of 33.06% from the latest price.
News
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam...
Bernstein starts BioNTech at Market Perform, sees high registration risk
Bernstein initiated coverage of BioNTech (BNTX) with a Market Perform rating and $96 price target Investors should pass on BioNTech at this time because of their aggressive pumitamig clinical developm...
BioNTech initiated with a Market Perform at Bernstein
Bernstein initiated coverage of BioNTech (BNTX) with a Market Perform rating and $96 price target
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was ...
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM
BioNTech NASDAQ: BNTX used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a rest...
BioNTech SE Transcript: AGM 2026
The AGM highlighted strong financials, strategic focus on oncology, and major leadership transitions. All management proposals, including board expansion and capital measures, were approved by large majorities. Manufacturing consolidation and a $1B share buyback were key initiatives.
Berenberg cuts BioNTech target, says shares ‘deeply’ undervalued
Berenberg lowered the firm’s price target on BioNTech (BNTX) to $140 from $155 and keeps a Buy rating on the shares. The firm says the current share price “deeply undervalues”…
BioNTech announces new $1B ADS repurchase program
BioNTech (BNTX) announced that it has authorized a new share repurchase program under which the company may repurchase American Depositary Shares, each representing one ordinary share of the company, ...
BioNTech Announces New ADS Repurchase Program
MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under whi...
BioNTech price target lowered to $158 from $171 at Canaccord
Canaccord lowered the firm’s price target on BioNTech (BNTX) to $158 from $171 and keeps a Buy rating on the shares. The firm said they lowered the target to reflect…
Germany says vaccine supply secure despite BioNTech production loss
A German government spokesperson said on Wednesday that the loss of BioNTech vaccine production in the country can be offset by other companies.
BioNTech to cut up to 1,860 jobs, close multiple global sites, Reuters reports
BioNTech (BNTX) is closing multiple global sites and cutting up to 1,860 jobs while initiating up to $1B in share buybacks, as it shifts Covid-19 vaccine production to Pfizer (PFE)…
BioNTech SE Earnings Call Transcript: Q1 2026
Q1 2026 revenues declined year-over-year due to lower COVID-19 vaccine demand, while oncology pipeline progress continued with strong late-stage data for pumitamig, gotistobart, and T-Pam. Full-year guidance was reaffirmed, and a €1B share buyback and manufacturing consolidation were announced.
BioNTech SE Earnings release: Q1 2026
BioNTech SE released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
BioNTech SE Slides: Q1 2026
BioNTech SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push
The company said it would exit operations at some manufacturing plants in Germany and Singapore, as well as sites it acquired as part of its CureVac takeover.
BioNTech reaffirms FY26 revenue view EUR2.000B- EUR2.300B
In 2026, BioNTech (BNTX) anticipates lower COVID-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets. The United States continues to be a…
BioNTech to close sites in Germany, Singapore affecting 1,860 staff
Germany's BioNTech said on Tuesday it would close sites affecting up to 1,860 jobs and buy back up to $1 billion worth of its shares, following the announcement of two co-founders quitting the COVID...
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
BioNTech SE (Nasdaq: BNTX) today reported financial results for the three months ended March 31, 2026 and provided an update on its corporate progress.
Two experimental drugs showed striking early results against pancreatic cancer
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Addit...
BioNTech price target raised to $130 from $128 at BofA
BofA raised the firm’s price target on BioNTech (BNTX) to $130 from $128 and keeps a Buy rating on the shares after the company reported positive Phase 2 data for…
BioNTech announce Phase 2 cohort of BNT323 met primary efficacy endpoint
BioNTech (BNTX) announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan, BNT323 or DB-1303, in patients with HER2-expressing, advanced endometrial ca...
BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.
BioNTech price target raised to $126 from $125 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on BioNTech (BNTX) to $126 from $125 and keeps an Overweight rating on the shares. The firm adjusted models among…